Research of Russian-American Anti-Cancer Center will be financed by American National Cancer Institute and Russian Foundation for Basic Research
Russian-American Anti-Cancer Center under Altai State University has become one of the winners in competition of fundamental research projects, which was held jointly by Russian Foundation for Basic Research and National Cancer Institute of the USA.
Project entitled “Immunosignatures for Detection of Breast Cancer Subtypes and Relapse Prediction”, which is supervised by executive director of Russian-American Anti-Cancer Center Andrey I. Shapoval, has been included into the list of 10 works that will receive financial backing. Independent evaluation was carried out by both Russian and American parties. On the whole, 57 applications were submitted to the competition in 2017.
“Due to our victory we received additional funding for study of breast cancer diagnosis. Russian-American Anti-Cancer Center under Altai State University has been conducting research in this area for several years already. This grant will provide us with an opportunity to expand our academic pursuits, test more samples, and evaluate the results of our research in a clinical setting,” Andrey I. Shapoval explained.
It is to be noted that project of Russian-American Anti-Cancer Center is one of strategic development projects of Altai State University. Appreciation and support rendered by Russian Foundation for Basic Research and National Cancer Institute of the USA confirm the fact that this research direction is relevant and demanded.
“We will be receiving funding for the project for 3 years. Annual amount of finance will equal 6 billion rubles from the Russian party and 100 thousand dollars from the American party,” Andrey I. Shapoval specified. “Our partners, Nadezhda Regional Cancer Center and Altai State Medical University will also participate in realization of the project.”
It is to be reminded that employees of Russian-American Anti-Cancer Center developed immunosignature for breast cancer in 2015, while in 2016 they proceeded to work on lung cancer as well.